Karyopharm Therapeutics (KPTI) investor relations material

Opening remarks and agenda

• The meeting was called to order at 9:01 A.M. Eastern Time on May 21, 2026, in a virtual format, ensuring stockholders had full participation rights.

• The chair introduced board members, executive team, legal counsel, and the independent auditor present for the meeting.

• Rules of conduct and procedures for participation and submitting questions were outlined at the start.

Shareholder proposals

• Five proposals were presented: election of two Class I directors, amendments to the 2022 Equity Incentive Plan and 2013 Employee Stock Purchase Plan, advisory approval of executive compensation, and ratification of the independent auditor.

Overview of voting outcomes

• A quorum was confirmed with a majority of shares represented.

• Both director nominees were elected to serve until the 2029 annual meeting.

• Amendments to increase shares in the equity and employee stock purchase plans were approved.

• Advisory approval of executive compensation and ratification of Ernst & Young as auditor for 2026 were both passed.

• Final voting results will be filed in a Form 8-K within four business days.